ArticleImmunity, inflammation and disease2022
Cdk2 suppresses IL-23 expression and the onset of severe acute pancreatitis.
Article in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape.Cell communication and signaling : CCS · 2026Article
- Macrophage-mimicking nanotherapy for attenuation of acute pancreatitis.Materials today. Bio · 2025Article
- Honokiol Prevents Intestinal Barrier Dysfunction in Mice with Severe Acute Pancreatitis and Inhibits JAK/STAT1 Pathway and Acetylation of HMGB1.Chinese journal of integrative medicine · 2024Article
- Analysis of factors influencing onset and survival of patients with severe acute pancreatitis: A clinical study.Immunity, inflammation and disease · 2024Article
- Cdk2 suppresses IL-23 expression and the onset of severe acute pancreatitis.Immunity, inflammation and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pancreatitis is a sudden inflammation of the pancreas. Although interleukin-23 (IL-23) is associated with the severity of acute pancreatitis, the underlying mechanism remains largely unknown. Herein, its regulatory mechanisms were explored in this study.
methodsRNA-sequencing analysis selected the differently expressed genes in cerulean-induced acute pancreatitis mice. Polymerase chain reaction analysis determined IL-23 expression in cyclin-dependent kinase 2 (Cdk2) short hairpin RNA (shRNA)-pretreated or DDB1-cullin-4-associated factor-2 (DCAF2)-overexpressed RAW264.7 cells or CDKs inhibitor AT7519/cullin ring-finger ubiquitin ligase inhibitor MLN4924-treated bone marrow-derived macrophages in the presence of lipopolysaccharides (LPS). Pancreatic damages were evaluated in AT7519-treated pancreatitis mice.
resultsPancreatitis mice displayed an increased expression on IL-23 and a decreased expression of Cdk2. Inhibiting Cdk2 by shRNA or AT7519 significantly induced IL-23 expression in LPS-treated RAW cells. Moreover, AT7519 treatment significantly aggravated the severity of acute pancreatitis in mice. Furthermore, AT7519 remarkably increased DCAF2 expression, which was also induced by MLN4924 no matter with or without AT7519 in vitro. On the contrary, overexpressing DCAF2 blocked the stimulatory effect of AT7519 on IL-23 expression.
conclusionCdk2 negatively regulates IL-23 expression by inhibiting DCAF2 in acute pancreatitis, indicating that Cdk2 might serve as a promising therapeutic target for acute pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.